Improve Outcomes for Older Allogeneic Transplant Recipients

Description

This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled. Evaluable subjects are defined as those participating in the exercise intervention.

Conditions

Allogeneic Transplantation

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled. Evaluable subjects are defined as those participating in the exercise intervention.

Intervening on Frailty to Improve Outcomes for Older Allogeneic Transplant Recipients

Improve Outcomes for Older Allogeneic Transplant Recipients

Condition
Allogeneic Transplantation
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Penn Medicine, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age 60 years or older.
  • 2. Planned allogeneic HCT in the next 1-6 months.
  • 3. Hematological malignancy as the indication for HCT.
  • 4. Pre-frail or frail by Fried frailty phenotype.
  • 1. Age 60 years or older.
  • 2. Planned allogeneic HCT or HCT within the last 30 days.
  • 3. Hematological malignancy as the indication for HCT.
  • 1. Comorbid disability or illness that prevents safe exercise.

Ages Eligible for Study

60 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Abramson Cancer Center at Penn Medicine,

Shannon McCurdy, MD, PRINCIPAL_INVESTIGATOR, Penn Medicine

Study Record Dates

2026-11-01